간편결제 가능보고서 주문 후, 연도 업데이트와 커스터마이징을 위해 당사에서 연락드릴 예정입니다.
상세 사항에 따라 가격이 변동될 수 있으니 참고 바랍니다.
기본 보고서는 영문으로 작성되며, PDF,PPT,DOCX(워드) 형식으로 제공 가능합니다.
보고서 전달 후에는 환불이 불가능하오니 양해 바랍니다.
평균 납기는 2주이며, 형식과 내용에 따라 달라질 수 있습니다.
요약
생물 제약 부형제 시장. Biopharmaceutical Excipient Manufacturing 시장-예측 (2023-2035)”. Biopharmaceutical Excipient 개요 Biopharmaceutical Excipient Manufacturing 시장 규모는 2023-2035 년 동안 4.9%의 CAGR에서 성장한 후 2035 년까지 5,888.0 백만 달러에 도달 할 것으로 예상됩니다.
Summary
Biopharmaceutical Excipients Market. Biopharmaceutical Excipient Manufacturing Market– Forecast (2023-2035)”. Biopharmaceutical Excipient Overview The Biopharmaceutical Excipient Manufacturing Market size is forecast to reach USD 5,888.0 Million by 2035, after growing at a CAGR of 4.9% during 2023-2035
Table of Contents
1.PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Biopharmaceutical Excipients
3.3. Properties of Ideal Excipients
3.4. Classification of Biopharmaceutical Excipients
3.4.1. Classification based on Route of Administration
3.4.2. Classification of Excipients based on Structure
3.4.3. Classification of Excipients based on Function
3.4.4. Classification based on Ability to Interfere with Metabolization and Efflux Mechanisms
3.5. Applications of Biopharmaceutical Excipients
3.6. Regulatory Scenario
3.7. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
4.2.5. Analysis by Type of Excipient based on Chemical Composition
· Carbohydrates
· Polyols
· Polymers
· Proteins / amino acids
· Salts
· Lipids
· Others
4.2.6. Analysis by Type of Excipient based on Function
· Surfactants
· Stabilizers
· Tonicity modifiers
· Bulking agents
· Buffering agents
· Solubility enhancers
· Drug delivery system
· Chelators
· Antimicrobials
· Antioxidants
· Others
4.2.7. Analysis by Type of Excipient based on Chemical Structure
· Organic
· Inorganic
4.2.8. Analysis by Scale of Operation
· Preclinical
· Clinical
· Commercial
4.2.9. Analysis by Type of Formulation
· Liquid or parenteral
· Solid
4.2.10. Analysis by Type of Biologic
· Vaccines
· Proteins / peptides
· Cell therapies
· Antibodies
· Blood products
4.2.11. Analysis by Global Regulatory Compliance
· United States Pharmacopoeia / United States Pharmacopoeia-National Formulary
· European Pharmacopoeia
· Japanese Pharmacopoeia
· British Pharmacopoeia
· China Pharmacopoeia
· American Chemical Society grade
· Indian Pharmacopoeia
· Food Chemical Codex
· Taiwan FDA
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Small Companies
5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
5.4.3. Company Competitiveness Analysis: Large Companies
5.4.4. Company Competitiveness Analysis: Very Large Companies
6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS
6.1. Chapter Overview
6.2. ABITEC
6.2.1. Company Overview
6.2.2. Biopharmaceutical Excipient Offerings
6.2.3. Manufacturing Facilities
6.2.4. Recent Developments and Future Outlook
6.3. Avantor
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Biopharmaceutical Excipient Offerings
6.3.4. Manufacturing Facilities
6.3.5. Recent Developments and Future Outlook
6.4. BASF Pharma
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Biopharmaceutical Excipient Offerings
6.4.4. Manufacturing Facilities
6.4.5. Recent Developments and Future Outlook
6.5. Corden Pharma
6.5.1. Company Overview
6.5.2. Biopharmaceutical Excipient Service Offerings
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments and Future Outlook
6.6. DFE Pharma
6.6.1. Company Overview
6.6.2. Biopharmaceutical Excipient Offerings
6.6.3. Manufacturing Facilities
6.6.4. Recent Developments and Future Outlook
6.7. Evonik
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Biopharmaceutical Excipient Offerings
6.7.4. Manufacturing Facilities
6.7.5. Recent Developments and Future Outlook
6.8. Kirsch Pharma
6.8.1. Company Overview
6.8.2. Biopharmaceutical Excipient Offerings
6.8.3. Manufacturing Facilities
6.8.4. Recent Developments and Future Outlook
6.9. Merck KGaA
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Biopharmaceutical Excipient Offerings
6.9.4. Manufacturing Facilities
6.9.5. Recent Developments and Future Outlook
6.10. Pfanstiehl
6.10.1. Company Overview
6.10.2. Biopharmaceutical Excipient Offerings
6.10.3. Manufacturing Facilities
6.10.4. Recent Developments and Future Outlook
6.11. Roquette
6.11.1. Company Overview
6.11.2. Biopharmaceutical Excipient Offerings
6.11.3. Manufacturing Facilities
6.11.4. Recent Developments and Future Outlook
6.12. Spectrum Chemical Manufacturing
6.12.1. Company Overview
6.12.2. Biopharmaceutical Excipient Offerings
6.12.3. Manufacturing Facilities
6.12.4. Recent Developments and Future Outlook
6.13. SPI Pharma
6.13.1. Company Overview
6.13.2. Biopharmaceutical Excipient Offerings
6.13.3. Manufacturing Facilities
6.13.4. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Excipient
7.3.5. Analysis by Type of Drug Molecule
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Analysis by Geography
7.3.6.1. Intercontinental and Intracontinental Deals
7.3.6.2. International and Local Deals
8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Company Size and Location of Headquarters
8.2.4. Analysis by Location of Expanded Facility
8.2.5. Analysis by Type of Excipient
8.2.6. Analysis by Type of Drug Molecule
8.2.7. Most Active Players: Analysis by Number of Recent Expansions
8.2.8. Geographical Analysis
8.2.8.1. Region-wise Distribution
8.2.8.2. Country-wise Distribution
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
9.3.1. Analysis by Company Size
9.3.2. Analysis by Scale of Operation
9.3.3. Analysis by Location of Manufacturing Facility
9.4. Concluding Remarks
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035
10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035
10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035
10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035
10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035
10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035
10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035
10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035
10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035
10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035
10.8.5. Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035
10.8.6. Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. DFE Pharma
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Jeannette M. Wetzel, Biopharma Sales Director
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
세금계산서 발행 문의
T. 070 8015 5940
보고서 주문 후, 연도 업데이트와 커스터마이징을 위해 당사에서 연락드릴 예정입니다.
상세 사항에 따라 가격이 변동될 수 있으니 참고 바랍니다.
기본 보고서는 영문으로 작성되며, PDF,PPT,DOCX(워드) 형식으로 제공 가능합니다.
보고서 전달 후에는 환불이 불가능하오니 양해 바랍니다.
평균 납기는 2주이며, 형식과 내용에 따라 달라질 수 있습니다.
요약
생물 제약 부형제 시장. Biopharmaceutical Excipient Manufacturing 시장-예측 (2023-2035)”. Biopharmaceutical Excipient 개요 Biopharmaceutical Excipient Manufacturing 시장 규모는 2023-2035 년 동안 4.9%의 CAGR에서 성장한 후 2035 년까지 5,888.0 백만 달러에 도달 할 것으로 예상됩니다.
Summary
Biopharmaceutical Excipients Market. Biopharmaceutical Excipient Manufacturing Market– Forecast (2023-2035)”. Biopharmaceutical Excipient Overview The Biopharmaceutical Excipient Manufacturing Market size is forecast to reach USD 5,888.0 Million by 2035, after growing at a CAGR of 4.9% during 2023-2035
Table of Contents
1.PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Biopharmaceutical Excipients
3.3. Properties of Ideal Excipients
3.4. Classification of Biopharmaceutical Excipients
3.4.1. Classification based on Route of Administration
3.4.2. Classification of Excipients based on Structure
3.4.3. Classification of Excipients based on Function
3.4.4. Classification based on Ability to Interfere with Metabolization and Efflux Mechanisms
3.5. Applications of Biopharmaceutical Excipients
3.6. Regulatory Scenario
3.7. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
4.2.5. Analysis by Type of Excipient based on Chemical Composition
· Carbohydrates
· Polyols
· Polymers
· Proteins / amino acids
· Salts
· Lipids
· Others
4.2.6. Analysis by Type of Excipient based on Function
· Surfactants
· Stabilizers
· Tonicity modifiers
· Bulking agents
· Buffering agents
· Solubility enhancers
· Drug delivery system
· Chelators
· Antimicrobials
· Antioxidants
· Others
4.2.7. Analysis by Type of Excipient based on Chemical Structure
· Organic
· Inorganic
4.2.8. Analysis by Scale of Operation
· Preclinical
· Clinical
· Commercial
4.2.9. Analysis by Type of Formulation
· Liquid or parenteral
· Solid
4.2.10. Analysis by Type of Biologic
· Vaccines
· Proteins / peptides
· Cell therapies
· Antibodies
· Blood products
4.2.11. Analysis by Global Regulatory Compliance
· United States Pharmacopoeia / United States Pharmacopoeia-National Formulary
· European Pharmacopoeia
· Japanese Pharmacopoeia
· British Pharmacopoeia
· China Pharmacopoeia
· American Chemical Society grade
· Indian Pharmacopoeia
· Food Chemical Codex
· Taiwan FDA
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Small Companies
5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
5.4.3. Company Competitiveness Analysis: Large Companies
5.4.4. Company Competitiveness Analysis: Very Large Companies
6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS
6.1. Chapter Overview
6.2. ABITEC
6.2.1. Company Overview
6.2.2. Biopharmaceutical Excipient Offerings
6.2.3. Manufacturing Facilities
6.2.4. Recent Developments and Future Outlook
6.3. Avantor
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Biopharmaceutical Excipient Offerings
6.3.4. Manufacturing Facilities
6.3.5. Recent Developments and Future Outlook
6.4. BASF Pharma
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Biopharmaceutical Excipient Offerings
6.4.4. Manufacturing Facilities
6.4.5. Recent Developments and Future Outlook
6.5. Corden Pharma
6.5.1. Company Overview
6.5.2. Biopharmaceutical Excipient Service Offerings
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments and Future Outlook
6.6. DFE Pharma
6.6.1. Company Overview
6.6.2. Biopharmaceutical Excipient Offerings
6.6.3. Manufacturing Facilities
6.6.4. Recent Developments and Future Outlook
6.7. Evonik
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Biopharmaceutical Excipient Offerings
6.7.4. Manufacturing Facilities
6.7.5. Recent Developments and Future Outlook
6.8. Kirsch Pharma
6.8.1. Company Overview
6.8.2. Biopharmaceutical Excipient Offerings
6.8.3. Manufacturing Facilities
6.8.4. Recent Developments and Future Outlook
6.9. Merck KGaA
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Biopharmaceutical Excipient Offerings
6.9.4. Manufacturing Facilities
6.9.5. Recent Developments and Future Outlook
6.10. Pfanstiehl
6.10.1. Company Overview
6.10.2. Biopharmaceutical Excipient Offerings
6.10.3. Manufacturing Facilities
6.10.4. Recent Developments and Future Outlook
6.11. Roquette
6.11.1. Company Overview
6.11.2. Biopharmaceutical Excipient Offerings
6.11.3. Manufacturing Facilities
6.11.4. Recent Developments and Future Outlook
6.12. Spectrum Chemical Manufacturing
6.12.1. Company Overview
6.12.2. Biopharmaceutical Excipient Offerings
6.12.3. Manufacturing Facilities
6.12.4. Recent Developments and Future Outlook
6.13. SPI Pharma
6.13.1. Company Overview
6.13.2. Biopharmaceutical Excipient Offerings
6.13.3. Manufacturing Facilities
6.13.4. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Excipient
7.3.5. Analysis by Type of Drug Molecule
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Analysis by Geography
7.3.6.1. Intercontinental and Intracontinental Deals
7.3.6.2. International and Local Deals
8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Company Size and Location of Headquarters
8.2.4. Analysis by Location of Expanded Facility
8.2.5. Analysis by Type of Excipient
8.2.6. Analysis by Type of Drug Molecule
8.2.7. Most Active Players: Analysis by Number of Recent Expansions
8.2.8. Geographical Analysis
8.2.8.1. Region-wise Distribution
8.2.8.2. Country-wise Distribution
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
9.3.1. Analysis by Company Size
9.3.2. Analysis by Scale of Operation
9.3.3. Analysis by Location of Manufacturing Facility
9.4. Concluding Remarks
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035
10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035
10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035
10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035
10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035
10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035
10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035
10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035
10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035
10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035
10.8.5. Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035
10.8.6. Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. DFE Pharma
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Jeannette M. Wetzel, Biopharma Sales Director
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
